Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation

Hafiz,Saly; Dennis,John C.; Schwartz,Dean; Judd,Robert; Tao,Ya‑Xiong; Khazal,Kamel; Akingbemi,Benson; Mo,Xiu-Lei; Abdel‑Mageed,Asim B.; Morrison,Edward; Mansour,Mahmoud

doi:10.3892/ijo.2012.1574

Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation

Authors:
- Saly Hafiz
- John C. Dennis
- Dean Schwartz
- Robert Judd
- Ya‑Xiong Tao
- Kamel Khazal
- Benson Akingbemi
- Xiu-Lei Mo
- Asim B. Abdel‑Mageed
- Edward Morrison
- Mahmoud Mansour
View Affiliations

Affiliations: Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA, Department of Biomedical Sciences, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL, USA, Urology and Oncology Research Laboratories, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, LA, USA
Published online on: July 25, 2012 https://doi.org/10.3892/ijo.2012.1574
Pages: 1373-1380

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The melanocortin receptors (MCRs 1-5) are G protein coupled-receptors (GPCRs) that regulate food intake, inflammation, skin pigmentation, sexual function and steroidogenesis. Their peptide ligands, the melanocortins, are α-, β- and γ-melanocyte-stimulating hormone and adrenocorticotropic hormone (ACTH) all of which are secreted from the anterior pituitary gland under hypothalamic control. MC2R binds ACTH but has no affinity for the other melanocortins and is, thereby, pharmacologically different from MCRs that bind those ligands. Evidence suggests that elevated GPCRs transactivate the androgen receptor (AR), the critical mediator of prostate cell growth, and consequently promote prostate cancer cell proliferation. It may be that reduced central melanocortin signaling is coincidental with reversal of prostate cancer cachexia, but no data are available on the expression of, or the role for, MCRs in prostate cancer. Here, we show that MCR (1-5) mRNAs are expressed in androgen-dependent LNCaP and androgen-independent PC3 and DU-145 human prostate cancer cell lines. Further, MC2R, the specific target of ACTH, is expressed in LNCaP, PC3 and DU-145 cells. Among the several synthetic MCR peptide ligands that we used, only ACTH promoted concentration-dependent cell proliferation in the three cell lines as shown by MTT cell proliferation assay. In LNCaP cells, the effect was additive with testosterone stimulation and was partially blunted with SHU9119, a non-selective MCR antagonist. In the same cells, ACTH induced cAMP production and increased AR nuclear labeling in immunocytochemical assays. Our observations suggest that MC2R is involved in prostate carcinogenesis and that targeting MC2R signaling may provide a novel avenue in prostate carcinoma treatment.

View Figures

View References

1	Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med. 333:1401–1405. 1995. View Article : Google Scholar : PubMed/NCBI
2	Oh WK and Kantoff PW: Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol. 160:1220–1229. 1998. View Article : Google Scholar : PubMed/NCBI
3	Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD and Sun Z: A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res. 35:2767–2776. 2007. View Article : Google Scholar : PubMed/NCBI
4	Huggins C: Endocrine-induced regression of cancers. Cancer Res. 27:1925–1930. 1967.PubMed/NCBI
5	Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490. 2004. View Article : Google Scholar : PubMed/NCBI
6	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar : PubMed/NCBI
7	Nguyen MM and Wang Z: Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer. Minerva Urol Nefrol. 60:15–29. 2008.PubMed/NCBI
8	Grossmann ME, Huang H and Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 93:1687–1697. 2001. View Article : Google Scholar : PubMed/NCBI
9	Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5:280–285. 1999. View Article : Google Scholar
10	Linja MJ and Visakorpi T: Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol. 92:255–264. 2004. View Article : Google Scholar : PubMed/NCBI
11	Vis AN and Schröder FH: Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 104:438–448. 2009. View Article : Google Scholar : PubMed/NCBI
12	Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol. 27(Suppl 2): 45–47. 1995.
13	Dorsam RT and Gutkind JS: G-protein-coupled receptors and cancer. Nat Rev Cancer. 7:79–94. 2007. View Article : Google Scholar : PubMed/NCBI
14	Daaka Y: G proteins in cancer: The prostate cancer paradigm. Sci STKE: re2. 2004.PubMed/NCBI
15	Mendiratta P, Armstrong AJ and George DJ: Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol. 9:S9–S19. 2007.PubMed/NCBI
16	Raj GV, Barki-Harrington L, Kue PF and Daaka Y: Guanosine phosphate binding protein coupled receptors in prostate cancer: A review. J Urol. 167:1458–1463. 2002. View Article : Google Scholar : PubMed/NCBI
17	Xia C, Ma W, Wang F, Hua SB and Liu M: Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene. 13:5903–5907. 2001. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Weng J, Cai Y, Penland R, Liu M and Ittmann M: The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate. 1:847–857. 2006. View Article : Google Scholar : PubMed/NCBI
19	Weng J, Wang J, Cai Y, et al: Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer. 113:811–818. 2005. View Article : Google Scholar : PubMed/NCBI
20	Yowell CW and Daaka Y: G protein-coupled receptors provide survival signals in prostate cancer. Clin Prostate Cancer. 1:177–181. 2002. View Article : Google Scholar : PubMed/NCBI
21	Sun L, Luo J, Mackey LV, et al: Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target. 19:719–730. 2011. View Article : Google Scholar : PubMed/NCBI
22	Gutkind JS: Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE: re1. 2000.PubMed/NCBI
23	McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the Protooncogene bcl-2 in the Prostate and Its Association with Emergence of Androgen-independent Prostate Cancer. Cancer Res. 52:6940–6944. 1992.PubMed/NCBI
24	Kasbohm EA, Guo R, Yowell CW, et al: Androgen receptor activation by G (s) signaling in prostate cancer cells. J Biol Chem. 280:11583–11589. 2005. View Article : Google Scholar : PubMed/NCBI
25	Merkle D and Hoffmann R: Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal. 23:507–515. 2011. View Article : Google Scholar : PubMed/NCBI
26	Luscombe CJ, French ME, Liu S, et al: Prostate cancer risk: Associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer. 85:1504–1509. 2001. View Article : Google Scholar : PubMed/NCBI
27	Wisse BE, Frayo RS, Schwartz MW and Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology. 142:3292–3301. 2001. View Article : Google Scholar : PubMed/NCBI
28	Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ and Cone RD: Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 91:789–798. 1997. View Article : Google Scholar : PubMed/NCBI
29	Roy S, Pinard S, Chouinard L and Gallo-Payet N: Adreno-corticotropin hormone (ACTH) effects on MAPK phosphorylation in human fasciculata cells and in embryonic kidney 293 cells expressing human melanocortin 2 receptor (MC2R) and MC2R accessory protein (MRAP)β. Mol Cell Endocrinol. 336:31–40. 2011.
30	Alwani RA, Neggers SJ, van der Klift M, et al: Cushing’s syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma. Pituitary. 12:280–283. 2009.
31	Mansour M, Schwartz D, Judd R, et al: Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol. 38:537–546. 2011.
32	Tao YX, Huang H, Wang ZQ, Yang F, Williams JN and Nikiforovich GV: Constitutive activity of neural melanocortin receptors. Methods Enzymol. 484:267–279. 2010. View Article : Google Scholar : PubMed/NCBI
33	Mansour M, White D, Wernette C, et al: Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor. Endocrine. 37:220–230. 2010. View Article : Google Scholar : PubMed/NCBI
34	Marinissen MJ and Gutkind JS: G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci. 22:368–376. 2001. View Article : Google Scholar : PubMed/NCBI
35	Labrie F, Belanger A, Dupont A, Luu-The V, Simard J and Labrie C: Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med. 16:475–492. 1993.PubMed/NCBI
36	Roy S, Rached M and Gallo-Payet N: Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. Mol Endocrinol. 21:1656–1669. 2007.
37	Cone RD: Studies on the physiological functions of the melanocortin system. Endocr Rev. 27:736–749. 2006. View Article : Google Scholar : PubMed/NCBI
38	Abdel-Malek Z, Swope VB, Suzuki I, et al: Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA. 92:1789–1793. 1995. View Article : Google Scholar : PubMed/NCBI
39	Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar
40	Liddle GW, Island DP, Ney RL, Nicholson WE and Shimizu N: Nonpituitary neoplasms and cushing’s syndrome: Ectopic ‘adrenocorticotropin’ produced by nonpituitary neoplasms as a cause of Cushing’s syndrome. Arch Intern Med. 111:471–475. 1963.
41	Gewirtz G and Yalow RS: Ectopic ACTH production in carcinoma of the lung. J Clin Invest. 53:1022–1032. 1974. View Article : Google Scholar : PubMed/NCBI
42	Singer W, Kovacs K, Ryan N and Horvath E: Ectopic ACTH syndrome: clinicopathological correlations. J Clin Pathol. 31:591–598. 1978. View Article : Google Scholar : PubMed/NCBI
43	Halkerston ID: Cyclic AMP and adrenocortical function. Adv Cyclic Nucleotide Res. 6:99–136. 1975.PubMed/NCBI